Investors

GLUCORA, SUPPORT HEALTHY GLUCOSE METABOLISM, NPN

January 23, 2015 by bnovak

EASTGATE BIOTECH CORP. RECEIVES AN NPN (NATURAL PRODUCT NUMBER) FOR ITS PRODUCT GLUCORA, DESIGNED TO SUPPORT HEALTHY GLUCOSE METABOLISM NPN GRANTED BY THE NATURAL AND NON-PRESCRIPTION HEALTH PRODUCTS DIRECTORATE (NHPD) OF HEALTH CANADASALT LAKE CITY and TORONTO, January 23, 2015 (PRNewswire/-) EastGate Biotech Corp. ...

Read more

EASTGATE BIOTECH CORP. NAMES NEW PRESIDENT

January 20, 2015 by bnovak

SALT LAKE CITY and TORONTO, January 20, 2015 (PRNewswire/-) Eastgate Biotech Corp., formerly EastGate Acquisitions Corporation (OTCBB: ETBI), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel formulations and alternative dosage forms of existing biologically active molecules has appointed ...

Read more

NEW STOCK SYMBOL ETBI

December 15, 2014 by bnovak

EASTGATE ACQUISITIONS ANNOUNCES NAME CHANGE TO EASTGATE BIOTECH CORP. AND NEW STOCK SYMBOL SALT LAKE CITY and TORONTO, December 15, 2014 (PRNewswire/-) Eastgate Biotech Corp., formerly EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations for the development of novel ...

Read more

Company’s Proprietary Intraoral Lorazepam Spray

November 3, 2014 by bnovak

EASTGATE ACQUISITIONS ANNOUNCES POSTER PRESENTATION OF THE COMPANY’S PROPRIETARY INTRAORAL LORAZEPAM SPRAY AT THE AMERICAN ASSOCIATION OF PHARMACEUTICAL SCIENTISTS (AAPS) CONFERENCE SALT LAKE CITY and TORONTO, November 3, 2014 (PRNewswire/-) EastGate Acquisitions Corporation ...

Read more

EASTGATE ACQUISITIONS AUGMENTS ITS SUB-MICRON SELF-NANOEMULSIFYING PLATFORM TECHNOLOGY

August 15, 2014 by bnovak

Broad spectrum of delivery forms is directed towards improving patient complianceSALT LAKE CITY and TORONTO, August 15 , 2014 (PRNewswire/-) EastGate ...

Read more

EASTGATE ACQUISITIONS ENTERS INTO A LICENSE AGREEMENT WITH PURINE PHARMA LLC FOR MARKETING AND DISTRIBUTION OF ITS NUTRACEUTICAL AND CONSUMER PRODUCT LINE

July 29, 2014 by bnovak

SALT LAKE CITY and TORONTO, September 29, 2014 (PRNewswire/-) EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of novel formulations and alternative dosage forms of existing biologically active molecules, announces that it has entered into a licensing ...

Read more

A transmucosal Lorazepam spray for treatment of acute seizures: Summary

July 29, 2014 by bnovak

The estimated annual incidence of prolonged epileptic seizures (status epilepticus) in the USA is about 150,000 cases and approximately 400,000 patients that suffer from repetitive seizures. These emergency conditions lead to 40,000 deaths in the USA every year. Control of status epilepticus and repetitive seizures ...

Read more

EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology

July 29, 2014 by bnovak

New pharmaceutical development opens up entry into blockbuster marketsSALT LAKE CITY and TORONTO, July 29, 2014 /PRNewswire/ -- EastGate AcquisitionsCorporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug deliveryinnovations in the development of improved novel formulations and alternative...

Read more

EASTGATE ACQUISITIONS RECEIVES RESEARCH GRANT FROM ONTARIO BRAIN INSTITUTE

June 25, 2014 by bnovak

SALT LAKE CITY and TORONTO, June 25, 2014 /PRNewswire/-- EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules ...

Read more

EASTGATE ACQUISITIONS ENTERS INTO WORKING COLLABORATION WITH LEADING NEUROLOGIST AT TORONTO WESTERN HOSPITAL

June 17, 2014 by bnovak

SALT LAKE CITY and TORONTO, June 17, 2014 /PRNewswire/ -- EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company exploring drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules expands on its pharmaceutical ...

Read more
RSS Icon